CYDY - CytoDyn to initiate 8 pre-clinical animal studies with leronlimab (PRO 140) for cancer February, 19 2019 08:35 AM CytoDyn Inc CytoDyn (OTCQB:CYDY) will conduct 8 pre-clinical studies on melanoma cancer, pancreatic, breast, prostate, colon, lung, liver and stomach cancer. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...